Evaluated by: David B. Kaminsky, M.D., FIAC, March 21, 2018
Original release date: May 29, 2018
Access to this course expires on: March 21, 2021
Faculty: Carol Farver, M.D., Jennifer Brainard, M.D.
- Define the pathologic features that dictate the use of molecular testing in the non-small cell lung cancer.
- Define the pathologic features that dictate the use of immunohistochemistry in the pathologic diagnosis of non-small cell lung cancer.
- Define the techniques used to identify the EML4/ALK rearrangement in lung cancer tissue specimens.
- Define the gene that has the most common targetable mutation in lung cancer.
$59.00 - $79.00